thyssenkrupp nucera doubles nine‑month order intake, halts SOEC mass‑production plan

Key highlights
  • Group order intake nearly doubled to €471m in the first nine months (+96%); Q3 intake €81m (+29%).
  • Won Moeve 300‑MW green hydrogen project including long‑term digital service package; partnered with BHEL to expand in India.
  • Decision to stop pursuing SOEC mass production triggers about €30m one‑time EBIT impairment.
  • Updated FY25/26 outlook: order intake €550–670m, Group sales €450–500m, Group EBIT €‑105m to €‑75m; gH2 sales now €100–130m.
Related project For subscribers
Milestones, plant data, involved companies (owners, investors, licensors, contractors) and news — kept up to date.
Under Construction
2022-12-01
2025
2026-03-02
2026-09-17
—
Operational / Completed · expected date for subscribers

Order intake and major contracts

Order intake rose to €81m in Q3 (+29%) and to €471m in the first nine months (+96%). In gH2 the company won Moeve’s 300‑MW new‑build green hydrogen plant, including a long‑term service package with digital twins, intelligent load management and operational simulations.

Segment performance

Group sales were €145m in Q3 (prior year €184m) and €354m for nine months (prior year €663m). Chlor‑Alkali (CA) showed strength: Q3 order intake €78m (+57%), Q3 sales €109m and Q3 EBIT €15m; nine‑month CA order intake €288m and EBIT €38m. Green Hydrogen (gH2) remained volatile: Q3 order intake €3m, Q3 sales €36m and EBIT €‑17m; nine‑month gH2 order intake €184m, nine‑month sales €80m and EBIT €‑107m.

SOEC strategy change

After a strategic review, the company will no longer pursue building its own SOEC mass‑production capacity, citing limited market readiness and investment economics. The decision causes approximately €30m of one‑time negative EBIT effects from impairments of pilot plant and capitalized development costs.

Balance sheet and cash

Net financial assets were €627m at June 30, 2026; order backlog €638m. Free cash flow for nine months was €‑26m and headcount stood at 1,076.

Outlook update

Management now expects FY25/26 order intake of €550–670m (previously €550–850m), Group sales €450–500m (previously €450–550m) and Group EBIT €‑105m to €‑75m (previously €‑80m to €‑30m). For gH2 sales the new range is €100–130m with EBIT €‑155m to €‑135m; CA outlook remains sales €320–400m and EBIT €45–65m.

Source: thyssenkrupp nucera

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

30 October 2026
Moeve 9M 2026: Clean CCS EBITDA €2,409m and record €885m capex

Robust operations and refining raised product volumes; large Spain-focused capex ramp-up for energy transition; net debt fell to €2.1bn; construction begun on Europe’s largest green hydrogen project.

27 October 2026
thyssenkrupp nucera: Three priorities to turn Europe's hydrogen ambition into industrial reality

Europe needs competitive, secure power at scale, resilient industrial capabilities and public interventions that unlock private capital to convert hydrogen targets into operating plants.

17 September 2026
Moeve starts Onuba — 300 MW first phase of Andalusian Green Hydrogen Valley

First phase delivers 300 MW (option +105 MW), ~45,000 tH2/yr, >€1bn phase investment, €304m public support and an expected >8,000 jobs across the value chain.

16 September 2026
Moeve brings Hy24 and COFIDES into Onuba phase of Andalusian Green Hydrogen Valley

First phase includes a 300 MW electrolyser (>€1bn capex), ~45,000 t H2/yr and ~250,000 t CO2 avoided; received €304m public funding and reached FID.

31 July 2026
Moeve H1 2026: €1.2bn Clean CCS EBITDA; 69% of H1 capex to energy transition in Spain

Net income €458m, capex €605m and operating cash flow €762m; leverage fell to 1.2x; groundbreaking for 300 MW Andalusian Green Hydrogen Valley on Sept 17; Galp merger talks continue.